GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients
Medical Research Archives · 2025 · 14 (2)
DOI: 10.18103/mra.v14i2.7325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2025. Verfasst von Kelly McKee und 1 weiteren Autor:innen.
Abstract (Originalsprache)
The multiantigen design and viral vector delivery platform of GEO-CM04S1 position this vaccine candidate as a next generation COVID-19 vaccine. Data generated to date indicate that the vaccine induces a durable, broadly specific and broadly functional humoral and cellular immune response to SARS-CoV-2 in both healthy adults and those with compromised immunity. The safety profile, as well as the breadth and magnitude of vaccine-induced T-cell responses supports its use in immunocompromised patients for prevention of severe COVID-19, addressing a critical unmet need. Targeting sequence-conserved structural proteins of this continually evolving pathogen should reduce the burdensome requirement for frequent updating and booster strategies designed to "chase the variant" to maintain efficacy.
Zitieren
APA
McKee, K., & Newman, M. (2025). GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients. Medical Research Archives, 14(2). https://doi.org/10.18103/mra.v14i2.7325
Vancouver
McKee K, Newman M. GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients. Medical Research Archives. 2025;14(2). doi:10.18103/mra.v14i2.7325
BibTeX
@article{McKee2025,
author = {McKee, Kelly and Newman, Mark},
title = {GEO-CM04S1: A Dual-Antigen COVID-19 Vaccine for Immunocompromised Patients},
journal = {Medical Research Archives},
year = {2025},
volume = {14},
number = {2},
doi = {10.18103/mra.v14i2.7325}
}
EUVIMED